Drug Discovery
Page 1 to 14 of 55 |     NEXT PAGE >
Advancing the drug discovery pipeline with early stage In vitro ADME and toxicity testing By Dr Maureen Bunger Summer 2017
With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its standard processes and procedures are as streamlined and effective as possible.

Read More

Raising the bar on the biologics potential Dr Michael Mouradian Summer 2017
In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment.

Read More

Pharma Derisking approaches to reduce liability to major metabolically-driven causes of drug attrition By Guy Webber Spring 2017
Intelligent application of early in vitro testing can help mitigate major drug development risks.

Read More

Three-dimensional cell culture: a rapidly emerging technique for drug discovery By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen Spring 2017
The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures. Today, 3D cell cultures are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease.

Read More

A strategic vision for 21st Century drug discovery. By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Winter 16/17
Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater understanding of the aetiology of diseases, it is generally accepted that the current approach to creating new small molecule therapeutics remains fundamentally inefficient.

Read More

Kinases and drug discovery: protein kinases as a validated drug target. By Professor Said A. Goueli Winter 16/17
The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and pharmaceutical industries. The payoff for the pharmaceutical industries has been substantial.

Read More

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu Winter 16/17
As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians to push away the originating basic scientists, lest their lofty impractical ideals disrupt a delicate balance of strategic compromise. Indeed many scientists may not understand the competing push and pull of efficacy versus toxicity and quality versus production costs.

Read More

Ion Channels - increasingly enticing targets for drug discovery. by Dr Douglas Krafte and Deborah Erickson Summer 2016
Drug discovery focused on ion-channel proteins began generating great value for pharmaceutical R&D programmes more than 30 years ago, giving rise to medicines still important in the pharmacopeia for treating human disease.

Read More

Reigniting pharmaceutical innovation through holistic drug targeting By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Summer 2016
Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic.

Read More

Drug Discovery in a Multi-Omics World By Mike Furness Winter 2015/16
Collectively rare diseases affect millions of people worldwide, but the number of people with any one condition is very small. Finding a cure is difficult as the market is not large enough to justify a big investment in drug development.

Read More

Therapeutic Drug Repurposing, Repositioning and Rescue Part IV: Financial model and analysis. By David M. Kauppi and Dr Stephen Naylor Winter 2015/16
There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) impacts all stakeholders involved in the therapeutic drug sector.

Read More

Ultra-sensitive measurement of protein and nucleic acid biomarkers may enable earlier disease detection and more effective therapies : Winter 06 By Dr Gregory Shipp Winter 2006
The pharmaceutical industry is striving to develop effective new therapies for diseases, ranging from cancers to cardiovascular and neurodegenerative disorders to a host of metabolic, infectious and genetic conditions, and is placing emphasis on treatments related to the early detection of disease.

Read More

Neutron scattering provides unique insights for drug R&D. Fall 10 By Dr Martyn Bull Fall 2010
Drug discovery and development is a long and expensive process. Techniques, such as computer modelling, that make the search for promising candidates easier are usually taken up enthusiastically.

Read More

Balancing a biologics pipeline portfolio. Spring 11 By Dr Herren Wu Spring 2011
Research into groundbreaking biologic therapies has significantly shifted the diagnosis and treatment paradigms for many disease categories, particularly in oncology, autoimmune, inflammation and neurology. Discovering and developing an innovative, first-in-class biologic has the potential to offer patients significant benefits as well as add substantially to a developer’s bottom-line as these medicines often become the new standard of care. But reaching this goal requires a difficult and seemingly insurmountable journey through the laboratory and the varying phases of clinical research.

Read More

Drug Discovery
Page 1 to 14 of 55 |     NEXT PAGE >